Effects of Intranasal Methamphetamine on Metacognition of Agency

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2007 Nov 29

PMID 18043908

Citations 8

Authors

Matthew G Kirkpatrick

Janet Metcalfe

Matthew J Greene

Carl L Hart

Affiliations

Soon will be listed here.

Abstract

Background: Although methamphetamine abuse has been associated with cognitive deficits, few studies have investigated the acute effects of the drug on complex cognitive performance. This study evaluated the acute effects of intranasal methamphetamine on a computerized task measuring metacognition of agency.

Procedure: Ten nontreatment seeking methamphetamine abusers (2F, 8M) completed this four-session, within-participant, double-blind laboratory study; during each session, participants received one of four doses (0, 12, 25, or 50 mg/70 kg) and completed the metacognition of agency task. In this task, participants were instructed to "catch" falling targets with a mouse and then provide metacognitive judgments about their feelings of control.

Results: Following placebo, judgments of agency were greater under optimal task conditions compared with less than optimal task conditions. Relative to placebo, the 12-mg dose improved task performance, increased judgments of agency under the optimal condition, and decreased judgments of agency under the less than optimal condition. By contrast, the larger doses (25 and 50 mg) increased judgments of agency only under the optimal condition but disrupted performance under the less than optimal condition.

Conclusion: These data show that a low intranasal methamphetamine dose enhanced judgments of agency and performance, while larger doses produced limited effects.

Citing Articles

Sense of control, selective attention, cognitive inhibition, and psychosocial outcomes after Retraining and Control Therapy (ReACT) in pediatric functional seizures.

Stager L, Mueller C, Morriss S, Szaflarski J, Fobian A Epilepsy Behav. 2023; 142:109143.

PMID: 36872138 PMC: 10164678. DOI: 10.1016/j.yebeh.2023.109143.

Cross domain self-monitoring in anosognosia for memory loss in Alzheimer's disease.

Chapman S, Colvin L, Vuorre M, Cocchini G, Metcalfe J, Huey E Cortex. 2018; 101:221-233.

PMID: 29518705 PMC: 5877321. DOI: 10.1016/j.cortex.2018.01.019.

Intimate insight: MDMA changes how people talk about significant others.

Baggott M, Kirkpatrick M, Bedi G, de Wit H J Psychopharmacol. 2015; 29(6):669-77.

PMID: 25922420 PMC: 4698152. DOI: 10.1177/0269881115581962.

Depression and executive dysfunction contribute to a metamemory deficit among individuals with methamphetamine use disorders.

Casaletto K, Obermeit L, Morgan E, Weber E, Franklin D, Grant I Addict Behav. 2014; 40:45-50.

PMID: 25222847 PMC: 4250506. DOI: 10.1016/j.addbeh.2014.08.007.

Judgements of agency in schizophrenia: an impairment in autonoetic metacognition.

Metcalfe J, Van Snellenberg J, DeRosse P, Balsam P, Malhotra A Philos Trans R Soc Lond B Biol Sci. 2012; 367(1594):1391-400.

PMID: 22492755 PMC: 3318770. DOI: 10.1098/rstb.2012.0006.

References

Mohs R, Tinklenberg J, Roth W, KOPELL B . Sensitivity of some human cognitive functions to effects of methamphetamine and secobarbital. Drug Alcohol Depend. 1980; 5(2):145-50. DOI: 10.1016/0376-8716(80)90191-x. View

Hart C, Haney M, Nasser J, Foltin R . Combined effects of methamphetamine and zolpidem on performance and mood during simulated night shift work. Pharmacol Biochem Behav. 2005; 81(3):559-68. DOI: 10.1016/j.pbb.2005.04.008. View

Simon S, Domier C, Sim T, Richardson K, Rawson R, Ling W . Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis. 2002; 21(1):61-74. DOI: 10.1300/j069v21n01_06. View

Hoffman W, Moore M, Templin R, McFarland B, Hitzemann R, Mitchell S . Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl). 2006; 188(2):162-70. DOI: 10.1007/s00213-006-0494-0. View

Thompson P, Hayashi K, Simon S, Geaga J, Hong M, Sui Y . Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004; 24(26):6028-36. PMC: 6729247. DOI: 10.1523/JNEUROSCI.0713-04.2004. View

Johanson C, Frey K, Lundahl L, Keenan P, Lockhart N, Roll J . Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl). 2006; 185(3):327-38. DOI: 10.1007/s00213-006-0330-6. View

Griffiths R, Bigelow G, Ator N . Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003; 70(3 Suppl):S41-54. DOI: 10.1016/s0376-8716(03)00098-x. View

Wiegmann D, Stanny R, McKay D, Neri D, McCardie A . Methamphetamine effects on cognitive processing during extended wakefulness. Int J Aviat Psychol. 1996; 6(4):379-97. DOI: 10.1207/s15327108ijap0604_5. View

Robbins T . Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J Comp Neurol. 2005; 493(1):140-6. DOI: 10.1002/cne.20717. View

10.

Cai J, Arnsten A . Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther. 1997; 283(1):183-9. View

11.

Gonzalez R, Rippeth J, Carey C, Heaton R, Moore D, Schweinsburg B . Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend. 2004; 76(2):181-90. DOI: 10.1016/j.drugalcdep.2004.04.014. View

12.

Hart C, Ward A, Haney M, Nasser J, Foltin R . Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work. Psychopharmacology (Berl). 2003; 169(1):42-51. DOI: 10.1007/s00213-003-1464-4. View

13.

Salo R, Nordahl T, Natsuaki Y, Leamon M, Galloway G, Waters C . Attentional control and brain metabolite levels in methamphetamine abusers. Biol Psychiatry. 2006; 61(11):1272-80. DOI: 10.1016/j.biopsych.2006.07.031. View

14.

Comer S, Hart C, Ward A, Haney M, Foltin R, FISCHMAN M . Effects of repeated oral methamphetamine administration in humans. Psychopharmacology (Berl). 2001; 155(4):397-404. DOI: 10.1007/s002130100727. View

15.

Zahrt J, Taylor J, Mathew R, Arnsten A . Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997; 17(21):8528-35. PMC: 6573725. View

16.

Kalechstein A, Newton T, Green M . Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci. 2003; 15(2):215-20. DOI: 10.1176/jnp.15.2.215. View

17.

Hart C, Haney M, Foltin R, Fischman M . Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology (Berl). 2002; 164(4):376-84. DOI: 10.1007/s00213-002-1225-9. View

18.

Silber B, Croft R, Papafotiou K, Stough C . The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl). 2006; 187(2):154-69. DOI: 10.1007/s00213-006-0410-7. View

19.

de Wit H, Crean J, Richards J . Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans. Behav Neurosci. 2000; 114(4):830-7. DOI: 10.1037//0735-7044.114.4.830. View

20.

London E, Berman S, Voytek B, Simon S, Mandelkern M, Monterosso J . Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry. 2005; 58(10):770-8. DOI: 10.1016/j.biopsych.2005.04.039. View